Head-to-head · WeighScore
Ilant Health vs ReadyRx
The verdict
ReadyRx takes it — 67.8/100 to 56.8/100.
ReadyRx grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. ReadyRx (readyrx.com) is a LegitScript-certified US telehealth provider offering compounded semaglutide from $179/mo and compounded tirzepatide from $255/mo, plus NAD+, sermorelin, glutathione, MIC+B12, and…
We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.
Factor by factor
The same six graded dimensions, side by side. See the methodology.
The numbers
| Metric | Ilant Health | ReadyRx |
|---|---|---|
| WeighScore | 56.8/100 | 67.8/100 |
| Grade | C | C |
| Scorecard rank | #407 | #156 |
| Semaglutide | Not disclosed | $179/mo (starting dose, compounded) |
| Tirzepatide | Not disclosed | $255/mo (starting dose, compounded) |
| Coverage | Coverage not published | All 50 states |
| Brand-name access | Compounded only | Compounded only |
| Oral / sublingual | Injection only | Injection only |
Graded #407 · C
Strengths
- Value-based, outcomes-driven obesity care model
- Includes GLP-1 medications with transparent drug pricing for sponsors
- Care team of board-certified obesity providers and behavioral specialists
- Dietitians and peer navigators support adherence
- Data-driven stratification targets the right interventions
Where it loses points
- Distributed via employers and health plans, not direct cash-pay
- Individuals generally cannot enroll without sponsor coverage
- No public consumer pricing for GLP-1
- Access gated behind organizational buyers
- Not suited to consumers wanting direct-to-door GLP-1
Graded #156 · C
Strengths
- LegitScript Certified — verifiable via the badge link in the footer
- Batch lab testing covers the right QA metrics for injectables: potency, sterility, pH, and endotoxicity
- Pricing shown publicly: $179/mo semaglutide, $255/mo tirzepatide
Where it loses points
- Pharmacy partners not named — only described as 'FDA-registered compounding pharmacies'
- Clinicians described as licensed and board-certified, but no names or credentials published
- 5,000+ member figure comes from a directory listing, not an independent audit
Also worth a look
Neither is our top-graded pick — CoreAge Rx leads the scorecard
Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.
Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.